Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Response to Nathan et al.
- Alexander R. Cobitz, MD, PHD1 and
- Phil Ambery, MRCP, MFPM2
- 1Medicines Development Centre—Metabolic, GlaxoSmithKline, King of Prussia, Pennsylvania;
- 2Cardiovascular, Metabolic, and Musculoskeletal Centre of Excellence, GlaxoSmithKline, Uxbridge, U.K.
- Corresponding author: Alexander R. Cobitz, alexander.r.cobitz{at}gsk.com
GlaxoSmithKline regrets the recommendation (1) of the recent American Diabetes Association/European Association for the Study of Diabetes consensus statement against the use of rosiglitazone for treatment of type 2 diabetes because it is contrary to scientific evidence.
The evidence regarding a possible association of rosiglitazone with increased risk of cardiovascular ischemic morbidity remains inconclusive. Data from clinical trials assessing cardiovascular outcomes are inconsistent with the hypotheses of increases in myocardial ischemia or death that have arisen from meta-analyses. No long-term clinical trials have confirmed an increased cardiovascular ischemic risk with rosiglitazone. Moreover, data from …
